Construction of a nomogram model to predict the risk of retinopathy of prematurity reactivate after intravitreal anti-vascular endothelial growth factor therapy: a retrospective study

ObjectiveTo explore the risk factors for the reactivate of retinopathy of prematurity (ROP) after intravitreal injection of anti-vascular endothelial growth factor (VEGF) and to construct a nomogram model to predict the risk of ROP reactivate.MethodsA retrospective analysis was conducted on 185 ROP...

Full description

Saved in:
Bibliographic Details
Main Authors: Ziyun Shen, Qingfei Hao, Tiantian Yang, Xiuyong Cheng
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Pediatrics
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fped.2024.1440437/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1841556742516768768
author Ziyun Shen
Qingfei Hao
Tiantian Yang
Xiuyong Cheng
author_facet Ziyun Shen
Qingfei Hao
Tiantian Yang
Xiuyong Cheng
author_sort Ziyun Shen
collection DOAJ
description ObjectiveTo explore the risk factors for the reactivate of retinopathy of prematurity (ROP) after intravitreal injection of anti-vascular endothelial growth factor (VEGF) and to construct a nomogram model to predict the risk of ROP reactivate.MethodsA retrospective analysis was conducted on 185 ROP children who underwent anti-VEGF treatment at the First Affiliated Hospital of Zhengzhou University from January 2017 to October 2023. They were randomly divided into a training set (129 cases) and a validation set (56 cases) at a ratio of 7:3. The training set was further divided into a reactivate group (n = 18) and a non-reactivate group (n = 111) based on whether ROP recurred after treatment. Multivariable logistic regression analysis was used to screen for risk factors for ROP reactivate. A nomogram model was constructed using R software and validated using the validation set. The discrimination, calibration, and clinical net benefit of the model were evaluated using the receiver operating characteristic curve (ROC curve), calibration curve, and decision curve analysis, respectively.ResultsMultivariable logistic regression analysis showed that the number of red blood cell transfusions, use of pulmonary surfactant (PS) 2 times or more, and preoperative fundus hemorrhage were independent risk factors for ROP reactivate (P < 0.05). The area under the ROC curve (AUC) of the training set was 0.810 (95% CI: 0.706–0.914), and that of the validation set was 0.756 (95% CI: 0.639–0.873). The Hosmer-Leme show goodness-of-fit test indicated a good fit of the model (P = 0.31). Calibration curve analysis and decision curve analysis suggested high predictive efficacy and clinical application value of the model.ConclusionsThe number of red blood cell transfusions, use of PS 2 times or more, and preoperative fundus hemorrhage are independent risk factors for ROP reactivate. The nomogram model constructed based on these factors has high predictive efficacy and clinical application value.
format Article
id doaj-art-b6fc5d771421433fadd7f90036d65808
institution Kabale University
issn 2296-2360
language English
publishDate 2025-01-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Pediatrics
spelling doaj-art-b6fc5d771421433fadd7f90036d658082025-01-07T06:41:18ZengFrontiers Media S.A.Frontiers in Pediatrics2296-23602025-01-011210.3389/fped.2024.14404371440437Construction of a nomogram model to predict the risk of retinopathy of prematurity reactivate after intravitreal anti-vascular endothelial growth factor therapy: a retrospective studyZiyun ShenQingfei HaoTiantian YangXiuyong ChengObjectiveTo explore the risk factors for the reactivate of retinopathy of prematurity (ROP) after intravitreal injection of anti-vascular endothelial growth factor (VEGF) and to construct a nomogram model to predict the risk of ROP reactivate.MethodsA retrospective analysis was conducted on 185 ROP children who underwent anti-VEGF treatment at the First Affiliated Hospital of Zhengzhou University from January 2017 to October 2023. They were randomly divided into a training set (129 cases) and a validation set (56 cases) at a ratio of 7:3. The training set was further divided into a reactivate group (n = 18) and a non-reactivate group (n = 111) based on whether ROP recurred after treatment. Multivariable logistic regression analysis was used to screen for risk factors for ROP reactivate. A nomogram model was constructed using R software and validated using the validation set. The discrimination, calibration, and clinical net benefit of the model were evaluated using the receiver operating characteristic curve (ROC curve), calibration curve, and decision curve analysis, respectively.ResultsMultivariable logistic regression analysis showed that the number of red blood cell transfusions, use of pulmonary surfactant (PS) 2 times or more, and preoperative fundus hemorrhage were independent risk factors for ROP reactivate (P < 0.05). The area under the ROC curve (AUC) of the training set was 0.810 (95% CI: 0.706–0.914), and that of the validation set was 0.756 (95% CI: 0.639–0.873). The Hosmer-Leme show goodness-of-fit test indicated a good fit of the model (P = 0.31). Calibration curve analysis and decision curve analysis suggested high predictive efficacy and clinical application value of the model.ConclusionsThe number of red blood cell transfusions, use of PS 2 times or more, and preoperative fundus hemorrhage are independent risk factors for ROP reactivate. The nomogram model constructed based on these factors has high predictive efficacy and clinical application value.https://www.frontiersin.org/articles/10.3389/fped.2024.1440437/fullanti-vascular endothelial growth factorretinopathy of prematurityreactivatenomogrampreterm
spellingShingle Ziyun Shen
Qingfei Hao
Tiantian Yang
Xiuyong Cheng
Construction of a nomogram model to predict the risk of retinopathy of prematurity reactivate after intravitreal anti-vascular endothelial growth factor therapy: a retrospective study
Frontiers in Pediatrics
anti-vascular endothelial growth factor
retinopathy of prematurity
reactivate
nomogram
preterm
title Construction of a nomogram model to predict the risk of retinopathy of prematurity reactivate after intravitreal anti-vascular endothelial growth factor therapy: a retrospective study
title_full Construction of a nomogram model to predict the risk of retinopathy of prematurity reactivate after intravitreal anti-vascular endothelial growth factor therapy: a retrospective study
title_fullStr Construction of a nomogram model to predict the risk of retinopathy of prematurity reactivate after intravitreal anti-vascular endothelial growth factor therapy: a retrospective study
title_full_unstemmed Construction of a nomogram model to predict the risk of retinopathy of prematurity reactivate after intravitreal anti-vascular endothelial growth factor therapy: a retrospective study
title_short Construction of a nomogram model to predict the risk of retinopathy of prematurity reactivate after intravitreal anti-vascular endothelial growth factor therapy: a retrospective study
title_sort construction of a nomogram model to predict the risk of retinopathy of prematurity reactivate after intravitreal anti vascular endothelial growth factor therapy a retrospective study
topic anti-vascular endothelial growth factor
retinopathy of prematurity
reactivate
nomogram
preterm
url https://www.frontiersin.org/articles/10.3389/fped.2024.1440437/full
work_keys_str_mv AT ziyunshen constructionofanomogrammodeltopredicttheriskofretinopathyofprematurityreactivateafterintravitrealantivascularendothelialgrowthfactortherapyaretrospectivestudy
AT qingfeihao constructionofanomogrammodeltopredicttheriskofretinopathyofprematurityreactivateafterintravitrealantivascularendothelialgrowthfactortherapyaretrospectivestudy
AT tiantianyang constructionofanomogrammodeltopredicttheriskofretinopathyofprematurityreactivateafterintravitrealantivascularendothelialgrowthfactortherapyaretrospectivestudy
AT xiuyongcheng constructionofanomogrammodeltopredicttheriskofretinopathyofprematurityreactivateafterintravitrealantivascularendothelialgrowthfactortherapyaretrospectivestudy